Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Shares Outstanding (2016 - 2025)

Iradimed (IRMD) has disclosed Shares Outstanding for 12 consecutive years, with $12.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding changed 0.4% to $12.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.7 million, a 0.4% change, with the full-year FY2024 number at $12.7 million, changed 0.39% from a year prior.
  • Shares Outstanding was $12.7 million for Q3 2025 at Iradimed, roughly flat from $12.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $12.7 million in Q3 2025 to a low of $12.3 million in Q1 2021.
  • A 5-year average of $12.6 million and a median of $12.6 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: grew 2.85% in 2021, then increased 0.27% in 2023.
  • Iradimed's Shares Outstanding stood at $12.5 million in 2021, then grew by 0.37% to $12.6 million in 2022, then increased by 0.55% to $12.7 million in 2023, then grew by 0.39% to $12.7 million in 2024, then rose by 0.09% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Shares Outstanding are $12.7 million (Q3 2025), $12.7 million (Q2 2025), and $12.7 million (Q1 2025).